Lantern Pharma

Lantern Pharma to present at ThinkEquity Conference on Oct 30, 2024, showcasing AI-driven oncology drug development. Their RADR® platform accelerates drug programs from AI insights to clinical trials in 2-3 years at $1.0-2.5 million per program, targeting a $15 billion USD market potential.

Lantern Pharma to host two October webinars highlighting RADR® AI platform's role in advancing cancer therapies, including collaborations with Actuate Therapeutics and discussions on drug candidates LP-184 and LP-284.

FDA fast track designation granted to LP-184 for glioblastoma treatment; phase 1b/2a trial to start late 2024 or early 2025. LP-184 targets DNA damage repair deficiency and has other FDA designations for pediatric cancers and pancreatic cancer.

The FDA granted fast track designation to LP-184 for treating glioblastoma (GBM). LP-184, a small-molecule alkylating agent causing tumor cell death via DNA damage, is under investigation in a phase 1a trial (NCT05933265) to assess its safety, tolerability, and maximum tolerated dose (MTD) in patients with solid tumors, including GBM. Once the MTD is determined, Lantern Pharma plans to advance LP-184 as STAR-001 for GBM and other CNS cancers.

FDA grants Fast Track Designation to Lantern Pharma's LP-184 for treating Glioblastoma, targeting a phase 1b/2a clinical trial for recurrent GBM to start in late 2024/early 2025.

AI is transforming drug development, enabling Big Pharma to reduce costs and speed up discoveries, while also allowing smaller biotechs to remain independent. AI-driven biotechs are forming partnerships to manage high development costs but have the potential to become competitors. AI could shorten drug development timelines significantly, potentially reducing discovery and preclinical stages to two to three years and clinical development to three to five years, helping biotechs overcome high costs. The global pharma-AI market is expected to grow at an 85% CAGR, though benefits may be incremental.

BioNTX introduces D. Jeff Keyser as the 2024 Dennis K. Stone Award recipient, recognizing his contributions to North Texas biotechnology. Keyser, with 40 years in the pharmaceutical industry, is CEO of Renibus Therapeutics and Chairman of Lantern Pharma. The award presentation will occur at the iC³ Life Science & Healthcare Innovation Summit on October 3.